Introduction {#S0001}
============

*Enterobacter hormaechei* is a species of gram-negative bacterium, belonging to the *Enterobacter cloacae complex* (ECC) and intestinal flora 75,[@CIT0001] which can exist in the intestinal tract of humans and animals, and is an opportunistic infectious pathogen. ECC was first described as nosocomial pathogens in the 1970s.[@CIT0002] Then, due to the dissemination of ESBLs and carbapenemases, ECC has become the third crucial drug-resistant pathogen in *Enterobacteriaceae*.[@CIT0003] In addition, it is one of the most common species that produces IMPs in *Enterobacteriaceae*.[@CIT0004] As the predominant species and the most commonly isolated nosocomial pathogen of ECC,[@CIT0005]--[@CIT0007] the infection rate of *E. hormaechei* is increasing year by year.[@CIT0008] So far, ESBLs and carbapenemases were detected in *E. hormaechei*, including *Klebsiella pneumoniae* carbapenemases-2 (KPC-2),[@CIT0009] KPC-4,[@CIT0007] New Delhi metallo-β-lactamase-1 (NDM-1),[@CIT0010] NDM-7,[@CIT0011] German-Imipenemase-1(GIM-1),[@CIT0012] extended spectrum beta-lactamases CTX-M-(15, 9, 2),[@CIT0009] SHV-12, TEM-1B,[@CIT0007] and so on. However, detection of Metallo-β-lactamase IMP-26 has not been described.

IMP-26 was firstly reported in *Pseudomonas aeruginosa* isolated from Singapore in 2008, which was similar to IMP-4 and this sequence was previously stored in the GenBank database as IMP-4, from an *Acinetobacter calcoaceticus* strain (No. ABC24668.1).[@CIT0013] Since then, this metallo-β-lactamase type has appeared in China,[@CIT0014],[@CIT0015] Australia, Philippines,[@CIT0016] Malaysia[@CIT0017] and Vietnam[@CIT0018] in succession. However, these reports indicated that IMP-26 is located on the chromosome or without reference to its location, and only two reports ever described a copy of *bla*~IMP-26~ on the plasmid.[@CIT0019],[@CIT0020]

Here, we identified a clinical isolate of *E. hormaechei* L51 producing both *bla*~IMP-26~ and *bla*~SHV-178~, and described the complete sequence of a conjugative IncHI2/2A plasmid. In addition, we performed phylogenetic analyses, S1-PFGE and southern blotting and drug resistance analysis to reveal the homology of isolate and the potential transmission mechanisms of *bla*~IMP-26~.

Materials and Methods {#S0002}
=====================

Bacterial Isolate and Susceptibility Testing {#S0002-S2001}
--------------------------------------------

The isolate L51 was discovered in a routine screening of the intestinal colonization by bacteria resistant to carbapenems in the First Affiliated Hospital of Zhejiang University (FAHZU) in Hangzhou since 2016. The species identity of the bacteria strain was determined using matrix-assisted laser desorption/ionization time-of-ﬂight mass spectrometry (MALDI-TOF MS) (Bruker, Bremen, Germany) and Sanger sequencing. The MIC values were determined using the agar dilution method and broth microdilution method. Results were interpreted following the Clinical and Laboratory Standards Institute (CLSI) standards,[@CIT0021] except tigecycline and colistin which were interpreted according to the 2018 EUCAST clinical breakpoints ([<http://www.eucast.org/clinical_breakpoints/>]{.ul}).

MLST, Conjugation Experiments, and S1-PFGE-Southern Blot Hybridization {#S0002-S2002}
----------------------------------------------------------------------

Multilocus sequence typing (MLST) was conducted as described previously.[@CIT0022] New alleles and sequence type were submitted to the MLST database and approved by PubMLST ([<http://pubmlst.org/ecloacae>]{.ul}). Conjugation experiments were carried out by co-incubation of *E. hormaechei* L51 and recipient *E. coli* EC600 at a 1:10 ratio in the LB broth at a temperature of 25°C. The transconjugants were coated on Mueller-Hinton medium with rifampicin (100 mg/L) and meropenem (2 mg/L). Colonies were selected from the selective medium and verified as *E. coli* EC600, then screened for *bla*~IMP-26~ by PCR and sequencing. The size and number of plasmids of *E. hormaechei* L51 were identified by S1-PFGE, as described previously,[@CIT0023],[@CIT0024] in addition, the location of *bla*~IMP-26~ was demonstrated according to southern blot and hybridization experiments using DIG-labeled *bla*~IMP~-probe.

Whole-Genome Sequencing and Bioinformatics Analysis {#S0002-S2003}
---------------------------------------------------

Genomic DNA was extracted using the Bacterial DNA Kit (Omega Bio-Tek, USA). Library construction was performed using a 350-bp small fragment genomic DNA library[@CIT0025] and a 10-kb fragment library. The sequencing was conducted using the Illumina HiSeq 4000-PE150 and PacBio Sequel platforms (Beijing Novogene Bioinformatics Technology Company, China), to obtain short-read data and long-read data, respectively. Hybrid assembly was performed using Unicycler v0.4.2 producing an Illumina assembly graph by short reads and building bridges by long reads.[@CIT0026] Genomic sequences were annotated using RAST 2.0 ([<http://rast.nmpdr.org/>]{.ul}). The Average Nucleotide Identity (ANI) values were calculated using OAT (Orthologous Average Nucleotide Identity Tool) and the proposed cut-off for species demarcation was 95\~96%. The resistome analysis was carried out using CARD ([<https://card.mcmaster.ca/>]{.ul}). Replicon type of plasmid was determined by Plasmid Finder 2.0 ([<https://cge.cbs.dtu.dk/services/PlasmidFinder/>]{.ul}), insertion sequence (IS) elements and transposons were identiﬁed using ISfinder ([<http://www-is.biotoul.fr/>]{.ul}), prophages were predicted by PHAST ([<http://phast.wishartlab.com/>]{.ul}) and CRISPR arrays were identified using CRISPR Finder ([<http://crispr.i2bc.paris-saclay.fr/>]{.ul}). Plasmid sequence alignment to the GenBank database was performed using BLASTn ([<https://blast.ncbi.nlm.nih.gov/Blast.cgi>]{.ul}). A circular map of the plasmids pEHZJ1 and pIMP26 was plotted using the BLAST Ring Image Generator (BRIG).[@CIT0027]

Phylogenetic Analysis {#S0002-S2004}
---------------------

A phylogenic tree was constructed using the Harvest suite, including Parsnp, a fast core-genome multi-aligner, and Gingr, a dynamic visual platform based on core-genome SNPs approach[@CIT0028] that incorporates 61 publicly available *E. hormaechei* genomes ([[Table S1](http://www.dovepress.com/get_supplementary_file.php?f=232514.pdf)]{.ul}). The genome of *E. hormaechei* SCEH020042 (NZ_CP028538.1) was used as the reference isolate.

GenBank Accession Numbers {#S0002-S2005}
-------------------------

The complete genome sequence of *E. hormaechei* L51 has been deposited to GenBank under the accession CP033102-CP033103.

Results {#S0003}
=======

Isolation and Identification of *E. hormaechei* L51 Harboring *bla~IMP-26~* and *bla~SHV-178~* {#S0003-S2001}
----------------------------------------------------------------------------------------------

A female patient, 16-year-old, was admitted to the department of gastroenterology of FAHZU in March 2016 and was diagnosed with Crohn disease. The patient had abdominal pain for more than 2 months. After admission, the amount of excrement of stool was very small, and it was mainly mushy. Stool was collected at the time of admission examination, then a strain of *Enterobacteriaceae* was isolated from the selection medium with meropenem (2mg/L) and designated as L51. The isolate was confirmed as *E. hormaechei subsp. hoffmannii* harboring *bla*~IMP-26~ and *bla*~SHV-178~ by MALDI-TOF MS and ANI analysis.

Antimicrobial Susceptibility Proﬁles {#S0003-S2002}
------------------------------------

AST revealed that the strain was resistant to amoxicillin-clavulanate, cefotaxime, ceftazidime, cefepime, meropenem, imipenem, ertapenem, aztreonam, gentamicin, tobramycin, ciprofloxacin, tetracycline, chloramphenicol and nitrofurantoin, and was intermediate to levofloxacin and fosfomycin. Among them, resistance to cefotaxime, ceftazidime, tetracycline and chloramphenicol was greater than 128 mg/L. In addition, the strain was sensitive to piperacillin-tazobactam, amikacin, tigecycline, trimethoprim-sulfamethoxazole and colistin ([Table 1](#T0001){ref-type="table"}).Table 1Antimicrobial Susceptibility Profile of *Enterobacter hormaechei* L51Drug ClassAntimicrobial DrugMIC (mg/L)R/I/SPenicillinsAmoxicillin-clavulanate128/64RPiperacillin-tazobactam^a^16/4SCephalosporinsCefotaxime≥128RCeftazidime≥128RCefepime16RCefpirome32RCarbapenemsMeropenem8RImipenem8RErtapenem8RMonobactamsAztreonam128RAminoglycosidesGentamicin128RAmikacin2STobramycin16RFluoroquinolonesCiprofloxacin1RLevofloxacin0.5ITetracyclinesTetracycline≥128RTigecycline1SOthersTrimethoprim-sulfamethoxazole≥8SChloramphenicol≥128RNitrofurantoin32RFosfomycin128IColistin0.5S[^2][^3]

Molecular Characteristics {#S0003-S2003}
-------------------------

PCR and sequencing further demonstrated the presence of *bla*~IMP-26~ in *E. hormaechei* L51. Based on sequence analysis of seven housekeeping genes, L51 was assigned to a new sequence type ST1103 (59-47-new338-new379-70-new146-6). The genome of L51 consisted of a circular chromosome of 5,018,729 bp and a plasmid of 343,918 bp. The GC content of chromosomes and plasmids was 54.8% and 48.4%, respectively. Four phages were found on the chromosome and two were found on the plasmid. In addition, two CRISPR arrays were identified on the chromosome ([[Table S2](http://www.dovepress.com/get_supplementary_file.php?f=232514.pdf)]{.ul}). A large number of drug-resistant genes were found in *E. hormaechei* L51, of these, 15 were encoded in the plasmid ([Table 2](#T0002){ref-type="table"}). The phylogenetic analysis of 61 *E. hormaechei* isolates ([Figure 1](#F0001){ref-type="fig"}) showed that various subspecies of *E. hormaechei* were separately aggregated, and *E. hormaechei* L51 and the reference isolate *E. hormaechei* SCEH020042 belonged to *E. hormaechei subsp. hoffmannii*. However, some *E. hormaechei subsp. steigerwaltii isolates* and some *E. hormaechei subsp. xiangfangensis* isolates were classified in the same cluster. In addition, 18,248 SNPs were identified between *E. hormaechei* L51 and the reference strain *E. hormaechei* SCEH020042.Table 2Antibiotic Resistance Genes in Plasmid of *Enterobacter hormaechei* L51Drug ClassCoding GenesGene Family, DescriptionPositionAminoglycoside*aac(3)-IIc*AAC(3)297,252--298,061*aac(6*ʹ*)-IIc*AAC(6ʹ)300,146--300,727Beta-lactamase*bla*~SHV-178~SHV beta-lactamase270,538--271,398*bla*~DHA-1~DHA beta-lactamase278,802--279,941*bla*~TEM-1~TEM beta-lactamase117,616--118,476*bla*~IMP-26~IMP beta-lactamase130,800--131,540Macrolide*ereA2*Macrolide esterase299,713--299,940Streptogramin*mrx*Macrolide phosphotransferase (MPH)90,384--91,622*mph(A)*91,619--92,524Phenicol*catII*Chloramphenicol acetyltransferase (CAT)261,382--262,023Fosfomycin*fosA5*Fosfomycin thiol transferase142,659--143,078Fluoroquinolone*qnrB4*Quinolone resistance protein (qnr)284,062--284,709Tetracycline*tet(D)*Major facilitator superfamily (MFS) antibiotic efflux pump258,586--259,770Sulphonamide*sul1*Sulfonamide resistant sul293,427--294,266Trimethoprim*dfrA19*Trimethoprim resistant dihydrofolate reductase dfr128,462--129,031 Figure 1The phylogenetic tree of 61 completed *E. hormaechei* genome generated by the Harvest suite, where *Enterobacter hormaechei* SCEH020042 is used as the standard strain. *Enterobacter hormaechei subsp. hoffmannii* strains and *E. hormaechei subsp. xiangfangensis* strains are marked in pink and blue, respectively.

Characteristics of IncHI2/2A Plasmid pEHZJ1 {#S0003-S2004}
-------------------------------------------

S1-PFGE and southern blot hybridization confirmed that the mega plasmid, pEHZJ1, contained *bla*~IMP-26~ ([Figure 2](#F0002){ref-type="fig"}). pEHZJ1 was 343,918 bp in length, with 318 CDSs and an average GC content of 48.4%. Replicon typing indicated that pEHZJ1 belonged to the IncHI2/2A plasmid. Conjugation experiments revealed that the transmission of *bla*~IMP-26~ from *E. hormaechei* L51 into *E. Coli* 600 was successful. pEHZJ1 carried a collection of replication initiation and conjugative transfer assembly proteins (*tra-par-trh-rep* region) and transcriptional regulators (*padR, tetR, merR, lysR, ygbI, ycjW*) and a large number of insertion sequences (ISs), which together constituted the structural backbone of the plasmid. In addition, the plasmid contained tellurium (\~15 kb), mercury (\~4 kb), arsenic (\~4.8 kb) operon that confers resistance to tellurium, mercury and arsenic, and the copies of *higA* and *higB* which encode toxin-antitoxin system proteins. pEHZJ1 also contained two-large MDR regions (MDR-1 and MDR-2) of \~46 kb and \~52 kb, respectively. In MDR-1 and MDR-2 regions, there were two copies of class 1 integron and numerous antibiotic resistance genes including to beta-lactam (*bla*~SHV-178~, *bla*~DHA-1~, *bla*~TEM-1~, *bla*~IMP-26~), to aminoglycoside (*aac(3)-IIc, aac(6*ʹ*)-IIc*), to tetracycline (*tet(D)*), to chloramphenicol (*catII*), to fosfomycin (*fosA5*), to fluoroquinolone (*qnrB4*), to sulphonamide (*sul1*) and to trimethoprim (*dfrA19*).Figure 2The identification of plasmid size using S1-PFGE (left) and southern blot and hybridization (right). The pEHZJ1 plasmid was between 336.5kbp and 398.4kbp, and was positive for a probe against *bla*~IMP-26.~

Class 1 Integron Carrying *bla~IMP-26~* Located in MDR-1 Region of pEHZJ1 {#S0003-S2005}
-------------------------------------------------------------------------

In MDR-1 region of pEHZJ1, a class 1 integron carrying gene cassette contained *bla*~IMP-26~, and a group II intron reverse transcriptase. And it was bracketed by ISs (IS*110*, IS*5*, IS*6* and IS*4*) and contained transposons belonging to the Tn*3* family ([Figure 3](#F0003){ref-type="fig"}). Moreover, the 5′-conserved segment (5′-CS) of the integron was adjacent to a resistance gene (*dfr19*), and the 3′-CS contained two coding sequences-*qacE∆1* and *sul1* (*orf5* was absent) and was adjacent to *fosA5*. The MDR-2 region contained another class 1 integron carrying gene cassette *aac(6*ʹ*)-IIc-ereA2-aac(3)-IIc-ereA2*, which was inserted into an IS*1247* backbone. For the integron in MDR-2, its 5′-CS was adjoining to IS*15DIV* and its 3′-CS region contained *qacE∆1* and *sul1*. The genes surrounding *bla*~IMP-26~ in pEHZJ1 were identical to pIMP26 (accession: MH399264), but different from *bla*~IMP-4~ in pEI1573 (accession: JX101693). In this study, *bla*~IMP-26~ or *bla*~IMP-4~ in pEHZJ1, pIMP26 or pEI1573 were closely followed by *intI1*, but the gene cassette *qacG, aacA4* and *catB* carried by the integron in pEI1573 was absent in pEHZJ1 ([Figure 3B](#F0003){ref-type="fig"}).Figure 3The genetic features of the pEHZJ1 plasmid.**Notes:** (**A**) Comparison of the pEHZJ1 plasmid sequence with pIMP26 using BRIG. The MDR-1 region, MDR-2 region and *tra-par-trh-rep* region are indicated in orange, pink and dark blue, respectively. Insert sequence and transposons are indicated in green. (**B**) Genetic features of MDR regions (MDR-1 and MDR-2) and a comparison of genes surrounding *bla*~IMP-26~ on pEHZJ1, pIMP26 (GenBank: MH399264.1) and pEI1573 (GenBank: JX101693.1). Gray regions denote regions that are homologous with \>95% nucleotide similarity. *bla*~IMP-26~ is indicated in red and class 1 integrons are marked by straight lines.

Discussion {#S0004}
==========

ECC is a complex group of bacterial species and is one of the leading causes of clinical nosocomial infections worldwide.[@CIT0029] Among *Enterobacter* spp. ECC is the most important complex group in human diseases, accounting for 65--75% of infections.[@CIT0002] As one of the most frequently isolated bacteria of ECC, *E. hormaechei* has become an important pathogen causing human clinical infection.[@CIT0030],[@CIT0031] Some reports exhibited that an *E. hormaechei* outbreak strain ever occurred nationwide in the Netherlands,[@CIT0032] in addition, this bacterium also appeared in several outbreaks of sepsis, most notably in the United States and Brazil.[@CIT0033] At present, it is recognized as capable of persisting in the hospital environment and developing resistance to multiple antibiotics.[@CIT0014],[@CIT0034] These facts imply that it will be a big potential threat to human health and may serve as a reservoir for drug resistance transmission in nosocomial infections.

Carbapenems were widely used as effective drugs in the treatment of multidrug-resistant bacterial infections. However, the presence and dissemination of carbapenemases in *Enterobacteriaceae* have emerged as a major challenge to modern medicine.[@CIT0012],[@CIT0035] In this study, we obtained a multidrug-resistant strain of *E. hormaechei* L51, harboring *bla*~IMP-26~ carbapenem resistance gene and *bla*~SHV-178~ ESBL gene. AST results showed this strain was high-level resistance to a variety of antimicrobial agents and were consistent with the genomic genes of the acquired resistance to antibiotics, suggesting that the drug resistance genes in chromosomes and pEHZJ1 were the major reason for multi-drug resistance of isolate L51 and our attention should be paid to it.

The phylogenetic analysis of 61 *E. hormaechei* isolates showed that some *E. hormaechei subsp. steigerwaltii* isolates and some *E. hormaechei subsp. xiangfangensis* isolates were classified in the same cluster. This may have been caused by the complex species composition of ECC making it difficult to identify the subspecies of a strain. In addition, 18,248 SNPs were identified between *E. hormaechei* L51 and the reference strain *E. hormaechei* SCEH020042, despite both strains belonged to the same subspecies. This suggested that strains within the subspecies of *E. homaechei* may be more divergent than expected. More complete genome sequences of *Enterobacter* isolates are required to improve the accuracy of identifying *E. hormaechei*.

Previous report has documented that SHV-type ESBL has strong genetic plasticity,[@CIT0036] in addition, pEHZJ1 IncHI2/2A plasmid contains both *bla*~SHV-178~ ESBL gene and *bla*~IMP-26~ carbapenem resistance gene, which was consistent with the hypothesis that IncHI2 plasmids carrying ESBL genes are more likely to acquire carbapenem resistance genes through horizontal transfer from integrons.[@CIT0003] Interestingly, it has ever demonstrated that IncHI2-type plasmids were involved in the propagation of *bla*~IMP-4~ among *Enterobacteriaceae* in Australia.[@CIT0037] Previous studies have shown that most of IncHI2 plasmids are transferable[@CIT0003] and frequently harbor carbapenemase genes,[@CIT0038],[@CIT0039] which idea was verified again in our study. In addition, transcriptional regulators, *tra-par-trh-rep* region, transposon and insertion sequences, and tellurium, mercury, arsenic operons were found in pEHZJ1, which backbone was similar to pIMP26,[@CIT0020] with 82% query coverage and 99% nucleotide identity. The presence of tellurium, mercury, and arsenic operons in pEHZJ1 was consistent with the conclusion that IncHI2 plasmids usually harbor toxin-antitoxin systems and heavy metal resistance from, Aoki et al.[@CIT0040] These metal-resistant operons may make the strains carrying IncHI2-type plasmid to be more viable in diverse environments.

Thus far, two reports have studied the genetic features surrounding *bla*~IMP-26~ in *P. aeruginosa*,[@CIT0017],[@CIT0018] and one in *Enterobacter cloacae*.[@CIT0020] Among them, the genetic context surrounding *bla*~IMP-26~ in *P. aeruginosa* was *intI1-bla*~IMP-26~-*qacG-aacA4-aac(6*ʹ*)-orf-catB3* and *intI1-bla*~IMP-26~-*qacG-aac(6*ʹ*)-Ib-aac(6*ʹ*)-orf3-orf4-catB3-dfrA1-tnpA-istB-orf5*, respectively. In our study, the genetic environment of *bla*~IMP-26~ was *intI1-bla*~IMP-26~-*ltrA-qacE∆1-sul1*, which was the same as in *E. cloacae*.[@CIT0020] Integron was first proposed by Strokes and Hall in 1989, which was a mobile DNA molecule with unique structure to capture and integrate exogenous genes.[@CIT0041]--[@CIT0043] There was one literature ever report that bacteria positive for integrons have higher incidences of resistance against antibacterial drugs beta-lactamase, aminoglycosides, monobactams and fluoroquinolones compared to bacteria without integrons.[@CIT0044] In recent years, the transfer of integrons harboring multiple drug-resistant gene cassettes or the joint transfer of two or more integrons into one isolate appears to be the basis for the rapid growth of MDR isolates.[@CIT0045] Our conjugative plasmid pEHZJ1 possesses two class 1 integrons and an array of drug resistance genes, which may well pose a threat for the treatment of nosocomial infection. Previous reports showed that *bla*~IMP-26~ has high genetic similarity to *bla*~IMP-4~, with only one position substitution at 145 (G-to-T change),[@CIT0013] moreover, *bla*~IMP-26~ and *bla*~IMP-4~ were generally carried by a class 1 integron.[@CIT0017],[@CIT0018],[@CIT0046] So, we selected pIMP26, pEI1573 and our plasmid pEHZJ1 for comparative analysis of genes surrounding *bla*~IMP-4~ and *bla*~IMP-26~. The results revealed that pIMP26 had the same genetic context surrounding *bla*~IMP-26~ as pEHZJ1, however genetic environment of *bla*~IMP-4~ in pEI1573 was *intI1-bla*~IMP-4~-*qacG-aacA4-catB-qacE∆1-sul1*. Although molecular characteristics of *bla*~IMP-4~ and *bla*~IMP-26~ are very similar, their genetic context also could be different. Future research is required to understand whether the genes surrounding *bla*~IMP~ affect the resistance of different strains.

Conclusion {#S0005}
==========

In summary, we describe the complete sequence of a mega conjugative IncHI2/2A plasmid carrying both *bla*~IMP-26~ and *bla*~SHV-178~ of *E. hormaechei* L51. Phylogenetic analysis based on core-genome SNPs revealed the huge differences between the subspecies of *E. hormaechei* and provided a reference view that more whole-genome sequencing data are needed for the more accurate identification of *E. hormaechei* subspecies. The spread of the IncHI2-type plasmid carrying IMP resistance genes in ECC is worth worrying about, although only one case was reported in this study. Our results also suggest that focusing on *E. hormaechei* will be important in future studies.
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